<?xml version="1.0" encoding="UTF-8"?>
<p id="Par53">Dipeptidyl peptidase-4 (DPP-4) inhibitors, a popular class of anti-diabetic medications, have been shown to achieve improved glycemic control by lowering HbA1C, without causing hypoglycemia, and are weight neutral [
 <xref ref-type="bibr" rid="CR16">16</xref>]. Because DPP-4 degrades particular incretins, such as SDF-1É‘, its inhibition is also linked with a potential mechanism to prevent vascular diseases. However, there is limited data demonstrating the potential cardiovascular effects of these medications. Only a few studies using either sitagliptin or saxagliptin have shown an increase in endothelial progenitor cells, and thus potential cardiovascular benefits, with DPP-4 therapy [
 <xref ref-type="bibr" rid="CR12">12</xref>, 
 <xref ref-type="bibr" rid="CR13">13</xref>, 
 <xref ref-type="bibr" rid="CR17">17</xref>].
</p>
